(Q36892799)

16 August 2017

1 reference

title

Sorafenib and sunitinib: novel targeted therapies for renal cell cancer (English)

1 reference

16 August 2017

Cheryl A Grandinetti

1

1 reference

16 August 2017

Barry R Goldspiel

series ordinal

2

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 August 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

27

1 reference

16 August 2017

issue

8

1 reference

16 August 2017

page(s)

1125-1144

1 reference

16 August 2017

cites work

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1125

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1125

Role of VHL gene mutation in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1125

Molecular genetics of familial renal cell carcinoma syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1125

Novel treatment strategies in clear-cell metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1125

Raf kinase as a target for anticancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1125

Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1125

Raf: a strategic target for therapeutic development against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1125

Immunocompetence and spontaneous regression of metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1125

Renal cell carcinoma--a review of 256 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1125

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1125

Prognostic factors and clinical trials of new agents in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1125

Prognostic factors for survival of patients with stage IV renal cell carcinoma: memorial sloan-kettering cancer center experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1125

Cytokine therapy: a standard of care for metastatic renal cell carcinoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1125

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1125

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1125

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1125

Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1125

Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1125

Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1125

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1125

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1125

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1125

Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1125

Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1125

Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1125

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1125

Quantitation of SU1 1248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1125

Sunitinib malate for the treatment of solid tumours: a review of current clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1125

Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1125

Sunitinib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1125

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1125

Mechanisms of hypertension associated with BAY 43-9006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1125

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1125

Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1125

Targeted agents for the treatment of advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1125

Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1125

Adjuvant therapy for renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1125

21 January 2018

Identifiers

DOI

10.1592/PHCO.27.8.1125

1 reference

16 August 2017

1 reference